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Abstract: General anesthesia impairs glutamate homeostasis at synapses by decreasing the production of gluta-
mate transporters. Glutamate transporters in astrocytes are important to preserve cognitive function and memory 
in hippocampus. In this study we investigated whether ulinastatin increases the number of glutamate transporters 
in glial cells. We used human astrocytes to demonstrate glutamate uptake in glial cells. The cells were divided into 
control and ulinastatin-treated groups. After incubation for 3 hours in serum free media, ulinastatin was admin-
istered to ulinastatin-treated group, then media was changed to HBSS buffer with 0.1 mM of glutamate. And we 
determined glutamate absorption by astrocytes by measuring glutamate levels in the media and astrocyte lysates at 
a time. We also measured levels of the glutamate transporters. In the ulinastatin-treated group, the total amount of 
glutamate was decreased, and the amount in astrocytes was significantly increased, compared to the control group. 
Expression of glutamate transporter 1 and glutamate aspartate transporter was significantly increased in the ulina-
statin group. In this study, administration of ulinastatin resulted in increased glutamate uptake by astrocytes. We 
also demonstrated glutamate transporters. Thus, we propose that ulinastatin may improve short memory impair-
ment and cognitive disorder after anesthesia by increasing the number of glutamate transporters.
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Introduction
Glutamate is the one of the major neurotrans-
mitters in brain, and the production and reup-
take of glutamates is predominantly performed 
by astrocytes, which are the main glial cells in 
the hippocampus [1, 2]. Disruption of gluta-
mate homeostasis in astrocytes is often 
observed in Alzheimer’s disease [3], general 
anesthesia, and other cognitive disorders. 
These cognitive disorders are caused by neuro-
vascular ischemic insult [4], chronic inflamma-
tion, or probably neurotoxicity of anesthetics [5, 
6]; these conditions disturb glutamate homeo-
stasis in astrocytes by reducing the production 
of glutamate transporters and the activity of 
glutamate transporters, and disrupt in gluta-
mate release [7, 8]. Therefore, maintaining glu-
tamate homeostasis in astrocytes is important 
to preserve glial function and cognitive function 
after anesthesia.
Ulinastatin is a serine protease inhibitor that 
has an anti-inflammatory effect by reducing 
reactive oxygen species (ROS) [9, 10]. It has 
been shown that ulinastatin reduces ROS via 
Toll-like receptor (TLR) 3 and 4, which are major 
receptors for ulinastatin [11]. Especially, TLR 3 
affects the production of glutamate transport-
ers such as glutamate aspartate transporter 
(GLAST) and glutamate transporter 1 (GLT-1) 
[12], which are major transporters for gluta-
mate uptake in astrocytes [13]. Therefore, in 
this study we investigated whether ulinastatin 
increases glutamate uptake in astrocytes 




The cells used in this study were human brain 
progenitor-derived astrocytes (Gibco, St. Louis, 
MO, USA). We divided the cells into control and 
ulinastatin-treated groups. Astrocytes were pre-
pared by plating 5×104 cells in each well of 
24-well plates, and the cells were transferred to 
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6-well plates to form a monolayer 1 day before 
the experiment. Three hours before starting the 
experiment, the medium was changed to medi-
um containing 0.1% fetal bovine serum (FBS). 
Ulinastatin (Halim Medical Company, Korea) 
was added to the study group at a concentra-
tion of 10,000 units/ml [14]. After 1 hour, the 
medium was replaced with Hank’s balanced 
salt solution (HBSS) containing 0.1 mM gluta-
mate (Sigma Chemical Co., St. Louis, MO, USA), 
and cells were incubated for a further 5 min-
utes in the presence or absence of 10,000 
units/ml ulinastatin. After incubation, the level 
of glutamate was simultaneously measured in 
the supernatant and cell lysate of both groups 
(Figure 1). 
Measurement of glutamate uptake 
We determined glutamate uptake by astrocytes 
by measuring the amount of glutamate in the 
media and in astrocyte lysates. We used this 
method rather than demonstrating glutamate 
transportation in real-time because we do not 
have the radioisotope system that is the pre-
ferred method for demonstrating the transmis-
sion of neurotransmitters in glial cells and 
neurons.
Measurement of glutamate absorption from 
media by astrocytes
Astrocyte cells were cultured in FBS-free 
Dulbecco’s minimal essential medium (DMEM) 
at 37°C and 5% CO2. At the end of the experi-
ments, the glutamate level in the medium was 
measured using a glutamate assay kit (Abcam 
Co., Cambridge, MA, USA) in are action mixture 
containing 50 μl supernatant, 90 μl assay mix, 
8 μl glutamate developer, and 2 μl glutamate 
enzyme mixture. After incubation at 37°C for 
30 minutes the absorbance was measured at 
450 nm using an ELISA reader uQuant (Bio-Tek 
Instruments.Inc, Winooski, VT, USA).
Figure 1. Experimental protocol. Effect of ulinastatin for glutamate reuptake in treated astrocytes. After glial cells 
were cultured with or without ulinastatin (10,000 unit/ml) for 1 hour, the medium were changed with glutamate 
uptake buffer and then the astrocytes were incubated with or without ulinastatin for 1 hour. The glutamate concen-
tration of supernatant and cell lysate was detected by glutamate assay kit. 
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Measurement of glutamate in astrocyte cell 
lysates
Cell lysates were prepared as follows. After 
incubation, the astrocytes were harvested by 
scraping in HBSS buffer, homogenized by soni-
cation for 3 seconds, and centrifuged at 12,000 
rpm for 10 min. After centrifugation, the super-
natant was collected and the protein amount of 
glutamate was determined by the Bradford 
method. 
Real-time PCR
Preparation of total RNA: Total RNA was 
extracted from astrocyte cell culture. Cells were 
homogenized in 1 ml of Trizol reagent (Life 
Technologies, Carlsbad, CA, USA) and total RNA 
was isolated according to the manufacturer’s 
protocol. The RNA concentration was deter- 
mined by spectrometry using Nanodrop (ND-
1000 spectrophotometer, Nanodrop Techno- 
logies, Wilmington DE, USA).
Real-time reverse transcription polymerase 
chain reaction (RT-PCR)
The expression levels of GLAST, GLT1, TLR-3, 
and TLR-4 mRNA were quantified by RT-PCR 
using LightCycler FastStart DNA Master SYBR 
Green I (Roche, Mannheim, Germany) accord-
ing to the manufacturer’s protocol. The reaction 
mixture (20 μl) contained LightCycler Fast Start 
DNA Master SYBR Green I, 4 mM MgCl2, 0.5 μM 
of primer pairs, and 2 μl of the cDNA as tem-
plate. The sequences of primer pairs are sum-
marized in Table 1. The PCR reaction was per-
formed at 95°C for 10 minutes, followed by 45 
cycles at 95°C for 10 seconds, the appropriate 
annealing temperature for 10 seconds, and 
72°C for size of amplicon (bp)/25 seconds. 
After amplification, melting analysis was per-
formed at 65°C for 15 seconds and 40°C for 
30 seconds. RT-PCR was performed in a 
LightCycler 1.5 (Roche Diagnostics). To control 
for variations, expression of all PCR products 
were normalized against that of beta actin.
Western blotting
To measure protein levels of the glutamate 
transporters GLAST and GLT-1, astrocytes were 
homogenized in lysis buffer (radio-immunopre-
cipitation buffer; Sigma, St. Louis, MO USA) 
containing a proteinase inhibitor Cocktail 
(Roche) to extract the proteins. Protein concen-
trations were determined by the Bradford meth-
od. Equal amounts of protein (60 μg) were sep-
arated by 8% sodium dodecyl sulfate polyacryl-
amide gel electrophoresis (SDS-PAGE) and 
transferred to membranes. Membranes were 
blocked with 5% skim milk in 1× tris-buffered 
saline (TBS) at room temperature for 1 hr. For 
identification of GLAST and GLT-1, the mem-
branes were incubated with a 1:1,000 dilution 
of rabbit monoclonal anti-GLAST antibody or 
rabbit polyclonal anti-GLT-1 primary antibody 
(Cell Signaling Technology, Beverly, MA, USA) 
overnight at 4°C. The membrane was washed 
three times in 1× TBST buffer and incubated 
with a 1:2,000 dilution of horseradish peroxi-
dase (HRP)-conjugated anti-rabbit IgG second-
ary antibody for detection of GLAST and GLT-1. 
For detection of actin as a normalization con-
trol, 1:3,000 diluted primary antibody (Sigma) 
and 1:5,000 diluted anti-rabbit IgG-HRP were 
used. An electro-chemiluminescence kit was 
used to develop the western blots (Amersham, 
Table 1. Primer sequences for real-time PCR
Gene Accession numbers Sequence Amplicon size Annealing temperature
TLR3 NM198791.1 5’-GGAGGGTCCAACTGGAGAAC-3’ 99nt 53°C
5’-AACCAGCTCTCAACCTTGGTA-3’
TLR4 CQI175880.1 5’-AACCAGCTCTCAACCTTGGTA-3’ 100nt 53°C
5’-CCACAGCCACCAGATTCTCT-3’
GLAST AF265360.1 5’-AAATGGGGAACTCCGTGATT-3’ 106nt 53°C
5’-ATCTTGGTTTCGCTGTCTGC-3’
GLT1 AY044832.1 5’-ACATGTCCACGACCATCATT-3’ 91nt 53°C
5’CCCAGCTGCTTCTTGAGTTT-3’
Beta actin NM_031144 5’-GGTCCTAGCACCAATGAAGA-3’ 105nt 53°C
5’-ATCTGCTGGAAGGTGGACAG-3’
Primer sequences of GLT-1, GLAST, TLR-3, and TLR-4 used for real-time PCR.
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Boston, MA, USA). Image J software was used 
for densitometry analysis.
Results
Glutamate levels in supernatants and cell ly-
sates
The glutamate level in media was significantly 
reduced in the ulinastatin-treated group, com-
pared to the control group. Moreover the total 
amount of glutamate in lysates of ulinastatin-
treated cells was increased almost 4-fold rela-
tive to the control group (Figure 2).
TLR-3 and TLR-4 expression by real-time PCR
We measured the expression of TLR-3 and 4 in 
astrocytes by real-time PCR at the end of incu-
Figure 2. Glutamate uptake in astrocytes. This graph shows Glutamate in supernatant was significantly reduced 
in the ulinastatin treated group, as compared to the control group. And total amount of glutamate in ulinastatin 
treated cells lysate was five times higher than those of control group. *P<0.05 compared with the control group. A: 
Glutamate concentration of cell supernatant. B: Glutamate concentration of cell lysate. 
Figure 3. Up-regulated the expression of TLR-3, 4. Up-regulation of TLR-3, -4 mRNA expressions for ulinastatin 
(10,000 unit/ml) in astrocytes. Level of TLR-3 and TLR-4 mRNA were analyzed by real time PCR. Control; astro-
cytes were incubated in FBS free medium without ulinastatin, treated ulinastatin; astrocytes were incubated in FBS 
free medium with ulinastatin (10,000 unit/ml). A: TLR3 mRNA expression level, B: TLR4 mRNA expression level. 
*P<0.05 compared with the control group.
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bation with or without ulinastatin. Both the 
expression of TLR-3 and TLR-4 were significant-
ly up-regulated after treatment with ulinastatin 
(Figure 3).
GLT-1 and GLAST expression by western blot 
and PCR analysis
GLT-1 and GLAST transporters were significant-
ly increased in the ulinastatin-treated group, as 
compared to the control group in both western 
blotting and PCR analysis (Figure 4).
Discussion
Nowadays, glial cells are thought to be func-
tional units rather than barriers of neurons. It is 
known that dysfunction of astrocytes is one 
cause of cognitive disorder or short-term mem-
ory loss [15, 16]. Astrocytes, also known col-
Figure 4. Up-regulation of GLAST and GLT-1. Up-regulation of glutamate transporter (GLAST and GLT1) in ulinastatin 
(10,000 unit/ml) treated mouse astrocytes. The astrocytes were analyzed by western blotting and real time PCR. 
The GLAST and GLT-1 protein band were quantified by densitometry and normalized for actin. Using the image J for 
densitometry analysis. ULI = ulinastatin. *P<0.05 compared with the control group. A: Western blotting of GLAST 
and GLT-1, B: Real time PCR of GLAST and GLT-1. 
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lectively as astroglia, are characteristic star-
shaped glial cells in the brain and spinal cord. 
The proportion of astrocytes in the brain is not 
well defined, but studies have found that the 
astrocyte proportion ranges from 20% to 40% 
of all glia in brain [17]. Astrocytes perform many 
functions, including biochemical support of 
endothelial cells that form the blood-brain bar-
rier, provision of nutrients to the nervous tis-
sue, maintenance of extracellular ion balance, 
and a role in repair [18]. They are dominantly 
located in hippocampus area, which has impor-
tant roles in the consolidation of information 
from short-term memory to long-term memory 
[19], and involved in the release and absorption 
of neurotransmitters like glutamate, ATP, and 
GABA by regulating neurotransmitter transport-
ers. Glutamate is the major excitatory transmit-
ter in the brain and, once released to synapses, 
is rapidly cleared by glutamate transporters 
thus limiting glutamate excitotoxicity [20]. 
Indeed, inhibition of glutamate reuptake elicits 
short-term memory inhibition [7, 21]. Therefore, 
glutamate transporters play a crucial role in 
physiological glutamate homeostasis and neu-
rotoxicity [22].
Neurotransmission is regulated by neurotrans-
mitter concentrations at synapses in the neuro-
nal circuits. Termination of neurotransmission 
is achieved by reuptake into presynaptic nerve 
terminals through high-affinity plasma mem-
brane transporters. GABAergic, serotoninergic, 
glutamatergic, and dopaminergic transporters 
are involved in the neurotransmission systems 
of memory and cognitive processes. GLAST 
(EAAT1) is a primary glutamate transporter in 
the forebrain [23]. Duerson et al. [7] showed a 
lack of GLAST in the hippocampusin patients 
with Alzheimer’s disease. Mookherjee P et al. 
[24] also showed that loss of GLT-1 accelerates 
cognitive function deficits in rat models of 
Alzheimer’s disease. Ischemic insult or neuro-
toxic agents like halogenated anesthetics 
reduce the expression of glutamate transport-
ers in astrocytes. Vinje et al. [25] reported that 
sevoflurane, a popular inhalation anesthetic, 
down-regulated glutamate transporters like 
GLAST and GLT-1 in glial cells in the brain. Lee 
S et al. [26] revealed that glutamate transport-
er type-3 (EAAT3) knockout mice had signifi-
cant cognitive impairment after exposure to 
isoflurane compared to wild-type mice.
Postoperative cognitive dysfunction (POCD) is a 
recognized clinical phenomenon that presents 
with a decline of cognitive functions after anes-
thesia and surgery [27]. Approximately 30-40% 
of patients have POCD at hospital discharge 
after non-cardiac surgery. The incidence is 10% 
more for elderly patients at 3 months after sur-
gery [6]. Although the cause of POCD is not 
clear, glutamatergic pathway is important to 
preserve cognitive function [28, 29], Rath et al. 
[8] reported that etomidate impaired glutamate 
homeostasis by reducing glutamate uptake in 
the cerebrocortical area, and Liachenko et al. 
[30] also revealed that isoflurane reduced glu-
tamate release as well as glutamate reuptake. 
In this study, we showed that expression of glu-
tamate transporters such as GLAST and GLT-1 
was increased after ulinastatin administration 
and demonstrated that the uptake of gluta-
mate into astrocytes was simultaneously 
increased. Therefore, we believe that adminis-
tration of ulinastatin might reduce the inci-
dence of POCD or other cognitive disorders 
because glutamate transporters decrease glu-
tamate toxicity by increasing the uptake of glu-
tamate and improve glutamate transporter 
production.
Ulinastatin (or urinary trypsin inhibitor, UTI) is a 
glycoprotein that acts as a trypsin inhibitor and 
potentiates local anti-proteolytic activity on the 
extracellular matrix (ECM), reduces the produc-
tion of ROS, and also suppresses neutrophil 
accumulation and activity via suppression of 
cytokine-dependent signaling pathways such 
as ERK1/2, JNK, NF-kB, or Egr-1 pathways [9, 
10]. Ulinastatin can be derived from urine or 
synthetically produced. In preclinical and clini-
cal studies, ulinastatin protects against acute 
lung injury, graft ischemia–reperfusion injury, 
loss of renal function after cardiopulmonary 
bypass, severe burn injury, septic shock, and 
brain injury [11]. Ulinastatin also has an 
immune-suppresive function through its effect 
on Toll-like receptors. Toll-like receptors are a 
class of proteins that play a key role in the 
innate immune system. They are single mem-
brane-spanning, non-catalytic receptors that 
are usually expressed in sentinel cells such as 
macrophages and dendritic cells and recognize 
structurally conserved molecules derived from 
microbes. Each type of toll-like receptor has 
specific ligands that bind different pathogens. 
Their signaling is followed by activation of the 
MyD88-dependent pathway or TRIF-dependent 
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pathway [31]. TLR-3 and -4 primarily signal 
through the TRIF-dependent pathway. Following 
activation by ligands of different origin, several 
reactions are possible via TLRs. Immune cells 
can produce signaling factors called cytokines, 
which trigger inflammation and induce adaptive 
immunityin dendritic cells [31]. Scumpia PO et 
al. [12] reported that up-regulated TLR-3 on 
astrocytes increases the production of gluta-
mate transporters such as GLAST and GLT-1, 
though the effect of TLR-4 to glutamate trans-
porters is still unclear. In this study we showed 
that ulinastatin upregulated the expression of 
toll-like receptors 3 and 4 on astrocytes, along 
with upregulated GLAST and GLT-1. Therefore, 
we propose that up-regulation of these gluta-
mate transporters was mediated possibly by 
up-regulation of TLR-3 and 4.
In conclusion, this study provides evidence that 
ulinastatin improves glutamate uptake by up-
regulating glutamate transporters such as 
GLAST and GLT-1. Furthermore, our results sug-
gest that the correlation between the expres-
sion of TLR-3, 4 and glutamate transporters. 
In order to understand the role of TLR-3, 4 
in glutamate transporter function, future stud-
ies using knock-out/in models are needed. 
Moreover, to confirm the effect of ulinastatin on 
cognitive function, we think that animal cogni-
tive-behavior study is required.
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